Protective effect of statin therapy on connective tissue growth factor induction by diabetes in vivo and high glucose in vitro

References

• Abdoli N, Heidari R, Azarmi Y, Eghbal MA. 2013. Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J Biochem Mol Toxicol 27:287–294
   Google Scholar
• Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB. 2008. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppressions osteoclastogenesis induced by receptor activator of nuclear factor-κB ligand through modulation of NFκB pathway. Int J Cancer 123:1733–1740
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 2004. Nephropathy in diabetes. Diabetes Care 27:579–583
   Google Scholar
• Aziz-Seible RS, Casey CA. 2011. Fibronectin: Functional character and role in alcoholic liver disease. World J Gastroenterol 17:2482–2499
   Google Scholar
• Aziz-Seible RS, McVicker BL, Kharbanda KK, Casey CA. 2011. Cellular fibronectin stimulates hepatocytes to produce factors that promote alcoholic-induced liver injury. World J Hepatol 3:45–55
   Google Scholar
• Blom IE, van Dijk AJ, de Weger RA, Tilanus MG, Goldschmeding R. 2001. Identification of human ccn2 (connective tissue growth factor) promoter polymorphisms. Mol Pathol 54:192–196
   PubMedGoogle Scholar
• Campese VM, Nadim MK, Epstein M. 2005. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol 16:S11–S17
   PubMed Web of Science ®Google Scholar
• Chaqour B, Yang R, Sha Q. 2006. Mechanical stretch modulates the promoter activity of the profibrotic factor CCN2 through increased actin polymerization and NF-κB activation. J Biol Chem 281:20608–20622
   Google Scholar
• Chen L, Charrier AL, Leask A, French SW, Bridstock DR. 2011. Ethanol-stimulated differentiated functions of human or mouse hepatic stellate cells are mediated by connective tissue growth factor. J Hepatol 55:399–406
   Web of Science ®Google Scholar
• Chiang TA, Yang YL, Yang YY, Hu MH, Wu PF, Liu SF, Huang RM, et al. 2010. Hyperosmolarity enhanced susceptibility to renal tubular fibrosis by modulating catabolism of type I transforming growth factor-β receptors. J Cell Biochem 109:663–671
   Google Scholar
• Cicha I, Garlichs CD, Daniel WG, Goppelt-Struebe M. 2004. Activated human platelets release connective tissue growth factor. Thromb Haemost 91:755–760
   PubMed Web of Science ®Google Scholar
• Dai Q, Lu J, Liu N. 2011. Fluvastatin attenuates myocardial interstitial fibrosis and cardiac dysfunction in diabetic rats by inhibiting over-expression of connective tissue growth factor. Chin Med J (Engl) 124:89–94
   PubMed Web of Science ®Google Scholar
• Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS. 2002. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signalling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci USA 99:8301–8305
   PubMed Web of Science ®Google Scholar
• Dendooven A, Gerritsen KG, Nguyen TQ, Kok RJ, Goldschmeding R. 2011. Connective tissue growth factor (CTGF/CCN2) ELISA: A novel tool for monitoring fibrosis. Biomarkers 16:289–301
   PubMed Web of Science ®Google Scholar
• Dichtl W, Dulak J, Frick M, Albert HF, Schwarzacher SP, Ares MP, Nilsson J, et al. 2003. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23:58–63
   PubMed Web of Science ®Google Scholar
• Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. 2001. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 133:1172–1180
   PubMed Web of Science ®Google Scholar
• Fioretto P, Mauer M. 2007. Histopathology of diabetic nephropathy. Semin Nephrol 27:195–207
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, Langham RG, Jerums G. 2003. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 26:2632–2636
   PubMed Web of Science ®Google Scholar
• Goppelt-Struebe M, Hahn A, Iwanciw D, Rehm M, Banas B. 2001. Regulation of connective tissue growth factor (CTGF*; ctgf) gene expression in human mesangial cells: Modulation by HMG CoA reductase inhibitors (statins). Mol Pathol 54:176–179
   PubMedGoogle Scholar
• Grotendorst GR, Okochi H, Hayashi N. 1996. A novel transforming growth factor β response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 7:469–480
   PubMedGoogle Scholar
• Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. 2007. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21:3355–3368
   PubMed Web of Science ®Google Scholar
• Heesom AE, Hibberd ML, Millward BA, Demaine AG. 1997. Polymorphism in the 5′-end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type 1 diabetes. Diabetes 46:287–291
   PubMed Web of Science ®Google Scholar
• Henninger C, Huelsenbeck J, Huelsenbeck S, Grösch S, Schad A, Lackner KJ, Kaina B, Fritz G. 2012. The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity. Toxicol Appl Pharmacol 261:66–73
   PubMed Web of Science ®Google Scholar
• Ito Y, Joles J, Bende R, Chand MA, Aten J, Kley L, Rabelink TJ, et al. 1998. CTGF in hypertensive nephrosclerosis of UNX-SHR. J Am Soc Nephrol 9:519 (Abstract)
   Google Scholar
• Jaffa AA, Usinger WR, McHenry MB, Jaffa MA, Lipstiz SR, Lackland D, Lopes-Virella M, et al. 2008. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J Clin Endocrinol Metab 93:1893–1900
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. 1991. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA 88:3628–3632
   PubMed Web of Science ®Google Scholar
• Kim SI, Han DC, Lee HB. 2000a. Lovastatin inhibits transformation growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol 11:80–87
   PubMed Web of Science ®Google Scholar
• Kim SI, Kim HJ, Han DC, Lee HB. 2000b. Effect of lovastatin on small GTP binding proteins and on TGF-β1 and fibronectin expression. Kidney Int Suppl 77:S88–S92
   PubMedGoogle Scholar
• Kobayashi T, Okada H, Inoue T, Kanno Y, Suzuki H. 2006. Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrol Dial Transplant 21:548–549
   Google Scholar
• Kono M, Nakamura Y, Suda T, Kato M, Kaida Y, Hashimoto D, Inui N, et al. 2011. Plasma CCN2 (connective tissue growth factor; CTGF) is a potential biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta 412:2211–2215
   PubMed Web of Science ®Google Scholar
• Kroening S, Solomovitch S, Sachs M, Wullich B, Goppelt-Struebe M. 2009. Regulation of connective tissue growth factor (CTGF) by hepatocyte growth factor in human tubular epithelial cells. Nephrol Dial Transplant 24:755–762
   Google Scholar
• Lam KS, Cheng IK, Janus ED, Pang RW. 1995. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38:604–609
   PubMed Web of Science ®Google Scholar
• Lawrencia C, Charrier A, Huang G, Brigstock DR. 2009. Ethanol-mediated expression of connective tissue growth factor (CCN2) in mouse pancreatic stellate cells. Growth Factors 27:91–99
   PubMed Web of Science ®Google Scholar
• Leask A, Abraham DJ. 2006. All in the CCN family: Essential matricellular signalling modulators emerge from the bunker. J Cell Sci 119:4803–4810
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470
   PubMed Web of Science ®Google Scholar
• Malenda A, Skrobanska A, Issat T, Winiarska M, Bil J, Oleszczak B, Sinski M, et al. 2012. Statins impair glucose uptake in tumor cells. Neoplasia 14:311–323
   PubMed Web of Science ®Google Scholar
• Mason RM. 2009. Connective tissue growth factor CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal 3:95–104
   PubMed Web of Science ®Google Scholar
• National Glycohemoglobin Standardization Program. Available from: www.ngsp.org/convert1.asp [last accessed 22 Jun 2013]
   Google Scholar
• Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, van Nieuwenhoven FA. 2006. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patient with diabetic nephropathy. Diabetes Care 29:83–88
   PubMed Web of Science ®Google Scholar
• Obrosova IG, Julius UA. 2005. Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. Curr Vasc Pharmacol 3:267–283
   PubMedGoogle Scholar
• Okada H, Inoue T, Kikuta T, Kato N, Kanno Y, Hirosawa N, Sakamoto Y, et al. 2008. Poly(ADP-ribose) polymerase-1 enhances transcription of the profibrotic CCN2 gene. J Am Soc Nephrol 19:933–942
   Google Scholar
• Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, Sugaya T, et al. 2005. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 16:133–143
   PubMed Web of Science ®Google Scholar
• Riser BL, Cortes P, DeNichilo M, Deshmukh PV, Chahal PS, Mohammed AK, Yee J, Kahkonen D. 2003. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report. Kidney Int 64:451–458
   PubMed Web of Science ®Google Scholar
• Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG. 2000. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25–38
   PubMed Web of Science ®Google Scholar
• Sarrab RM, Lennon R, Ni L, Wherlock MD, Welsh GI, Saleem MA. 2011. Establishment of conditionally immortalized human glomerular mesangial cells in culture, with unique migratory properties. Am J Physiol Renal Physiol 301:F1131–F1138
   Google Scholar
• Suzuki D, Toyoda M, Umezono T, Uehara G, Zhang SY, Sakai T, Nishina M, et al. 2003. Glomerular expression of connective tissue growth factor mRNA in various renal diseases. Nephrology (Carlton) 8:92–97
   Google Scholar
• Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, et al. On behalf of the Toronto Diabetic Neuropathy Expert Group. 2010. Diabetes neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of severity, and treatments. Diabetes Care 33:2285--2293
   Google Scholar
• The Expert Committee on the diagnosis and classification of diabetes mellitus. 2003. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26:S5–S20
   PubMed Web of Science ®Google Scholar
• Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, et al. 1997. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20:1891–1895
   PubMed Web of Science ®Google Scholar
• Viswanathan V, Tilak P, Kumpatla S. 2012. Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study. Indian J Med Res 136:46–53
   PubMed Web of Science ®Google Scholar
• Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, Schaefer R, Mason RM. 2005. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48:2650–2660
   PubMed Web of Science ®Google Scholar
• Wahab NA, Brinkman H, Mason RM. 2001. Uptake and intracellular transport of the connective tissue growth factor: a potential mode of action. Biochem J 359:89--97
   Google Scholar
• Wahab NA, Weston BS, Roberts T, Mason RM. 2002. Connective tissue growth factor and regulation of the mesangial cell cycle: Role in cellular hypertrophy. J Am Soc Nephrol 13:2437–2445
   PubMedGoogle Scholar
• Wang YJ, Fu GS, Chen FM, Wang H. 2009. The effect of valsartan and fluvastatin on the connective tissue growth factor expression in experimental diabetic cardiomyopathy. Zhonghua Nei Ke Za Zhi 48:660–665
   Google Scholar
• Weston BS, Wahab NA, Mason RM. 2003. CTGF mediates TGF-β-induced fibronectin matrix deposition by upregulating active α5β1 integrin in human mesangial cells. J Am Soc Nephrol 14:601–610
   PubMed Web of Science ®Google Scholar
• Yang B, Hodgkinson A, Oates P, Millward BA, Demaine AG. 2008. High glucose induction of DNA binding activity of the transcription factor NFκB in patients with diabetic nephropathy. Biochim Biophys Acta 1782:295–302
   PubMed Web of Science ®Google Scholar
• Yang B, Hodgkinson A, Shaw N, Rowe M, Millward B, Demaine A. 2011. High glucose induced NFκB and PARP-1 binding activities to the connective tissue growth factor gene in human podocytes and HK2 cell lines. Diabetic Med 28:62 (Abstract)
   Google Scholar